קומדין 10 מג
taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 10 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
ליקסיאנה 15 מג
medison pharma ltd - edoxaban as tosylate - טבליות מצופות פילם - edoxaban as tosylate 15 mg - edoxaban
ליקסיאנה 30 מג
medison pharma ltd - edoxaban as tosylate - טבליות מצופות פילם - edoxaban as tosylate 30 mg - edoxaban
ליקסיאנה 60 מג
medison pharma ltd - edoxaban as tosylate - טבליות מצופות פילם - edoxaban as tosylate 60 mg - edoxaban
אנגריד 0.5
rafa laboratories ltd - anagrelide as hydrochloride - קפסולות - anagrelide as hydrochloride 0.5 mg - anagrelide - anagrelide - treatment for essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms.
פלויקס 75 מג
sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid
פרסוגרל - תרימה 10 מג
trima israel pharmaceutical products maabarot ltd - prasugrel - טבליות מצופות פילם - prasugrel 10 mg - prasugrel
ברילינטה 60 מג
astrazeneca (israel) ltd - ticagrelor - טבליות מצופות פילם - ticagrelor 60 mg - ticagrelor
פרסוגרל טבע 10 מג
abic marketing ltd, israel - prasugrel as hydrobromide - טבליות מצופות פילם - prasugrel as hydrobromide 10 mg - prasugrel
פרסוגרל טבע 5 מג
abic marketing ltd, israel - prasugrel as hydrobromide - טבליות מצופות פילם - prasugrel as hydrobromide 5 mg - prasugrel